CSL's gene therapy for haemophilia B HEMGENIX (etranacogene dezaparvovec) has become the first treatment approved to be funded via the UK's 'Innovative Medicines Fund'.
CSL's gene therapy becomes the first funded via the UK's 'Innovative Medicines Fund'
July 5, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit
